IMEXF (Imagin Medical) ROCE %: 0.00% (As of Jun. 2023)


What is Imagin Medical ROCE %?

Imagin Medical IMEXF -99.00% ROCE % is 0.00% as of Jun. 2023.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Imagin Medical's annualized ROCE % for the quarter that ended in Jun. 2023 was 0.00%.

Imagin Medical  (OTCPK:IMEXF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Imagin Medical ROCE % Related Terms

Imagin Medical ROCE % Historical Data

* Premium members only.

The historical data trend for Imagin Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imagin Medical ROCE % Chart

Imagin Medical Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -291.75 -108.54 -490.64 0.00 0.00

Imagin Medical Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Imagin Medical ROCE % Calculation

Imagin Medical's annualized ROCE % for the fiscal year that ended in Sep. 2022 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Sep. 2022 )  (A: Sep. 2021 )(A: Sep. 2022 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Sep. 2022 )  (A: Sep. 2021 )(A: Sep. 2022 )
=-1.862/( ( (0.612 - 9.719) + (1.013 - 11.01) )/ 2 )
=-1.862/( (-9.107+-9.997)/ 2 )
=-1.862/-9.552
=19.49 %

Imagin Medical's ROCE % of for the quarter that ended in Jun. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2023 )  (Q: Mar. 2023 )(Q: Jun. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2023 )  (Q: Mar. 2023 )(Q: Jun. 2023 )
=6.632/( ( (0.835 - 11.194) + (0.841 - 9.846) )/ 2 )
=6.632/( ( -10.359 + -9.005 )/ 2 )
=6.632/-9.682
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 0.00% mean?
Imagin Medical (IMEXF) has a ROCE % of 0.00% as of Jun. 2023.
Is Imagin Medical's ROCE % too high?
Imagin Medical's current ROCE % is 0.00%.
How does Imagin Medical's ROCE % compare to ABT and SYK?
Imagin Medical's ROCE % of 0.00% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imagin Medical's current ROCE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagin Medical stock overvalued right now?
Imagin Medical (IMEXF) has a current ROCE % of 0.00%. The current ROCE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Imagin Medical (IMEXF), the current ROCE % is 0.00% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Imagin Medical Business Description

Address 890 West Pender Street, Suite 600, Vancouver, BC, CAN, V6C 1J9
Imagin Medical Inc is a Urologic Oncology company developing technologies to visualize and treat urologic cancers, including bladder and prostate cancer, through minimally invasive surgery. The company's first product, the i/Blue Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting bladder cancer, helping to improve the surgical management of this disease. Imagin's follow-on product, the enCAGE Coil is a device with 510(k) clearance for soft tissue ablation. Imagin intends to refine the disposable bipolar radio frequency-based probe for use in the treatment of prostate cancer and benign prostate hypoplasia (BPH) and submit appropriate FDA premarket applications for the new indications.